ARS Pharmaceuticals appoints Donn Casale as CEO, replacing Richard Lowenthal terminated without cause

ARS Pharmaceuticals, Inc.

Donn Casale, previously President, appointed CEO effective July 7, 2026.
Richard Lowenthal terminated without cause on July 6, 2026.
Casale also appointed to Board as Class III director until 2029 annual meeting.
No details on compensation or transition provided in the filing.

item 5.02

Featured in Daily 8-K Digest

Selected #1 for 2026-07-07. Read digest

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Donn Casale

Chief Executive Officer

SPRY · ARS Pharmaceuticals, Inc.

Effective: 2026-07-07
Filed: July 7, 2026, 4:38 PM ET

On July 7, 2026, the Board of Directors (the “Board”) of ARS Pharmaceuticals, Inc. (the “Company”) appointed the Company’s current President Donn Casale as the Company’s Chief Executive Officer, effective immediately, replacing Richard Lowenthal in such capacity.

Appointed

Donn Casale

Class III director

SPRY · ARS Pharmaceuticals, Inc.

Effective: 2026-07-07
Filed: July 7, 2026, 4:38 PM ET

Mr. Casale was also concurrently appointed to the Board as a Class III director, to serve until the Company’s 2029 annual meeting of stockholders.

Departed

Richard Lowenthal

Chief Executive Officer

SPRY · ARS Pharmaceuticals, Inc.

Effective: 2026-07-06
Successor: Donn Casale
Filed: July 7, 2026, 4:38 PM ET

Mr. Lowenthal was notified on July 6, 2026 that his employment was being terminated without cause, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Donn Casale was appointed as Chief Executive Officer at ARS Pharmaceuticals, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On July 7, 2026, the Board of Directors (the “Board”) of ARS Pharmaceuticals, Inc. (the “Company”) appointed the Company’s current President Donn Casale as the Company’s Chief Executive Officer, effective immediately, replacing Richard Lowenthal in such capacity.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Donn Casale was appointed as Class III director at ARS Pharmaceuticals, Inc..

Action: appointed
Role: Class III director

Exact text from the filing

Mr. Casale was also concurrently appointed to the Board as a Class III director, to serve until the Company’s 2029 annual meeting of stockholders.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard Lowenthal departed as Chief Executive Officer at ARS Pharmaceuticals, Inc..

Action: terminated without cause
Role: Chief Executive Officer

Exact text from the filing

Mr. Lowenthal was notified on July 6, 2026 that his employment was being terminated without cause, effective immediately.

View on SEC.gov

ARS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-297554

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.